11 results on '"Ide, Kazuki"'
Search Results
2. Intergenerational comparison of 5-HT3RA in the prevention of chemotherapy-induced nausea and vomiting in gastric cancer patients receiving cisplatin-based chemotherapy: an observational study using a Japanese administrative claims database.
- Author
-
Kunitomi, Yuji, Nakashima, Masayuki, Seki, Tomotsugu, Ide, Kazuki, and Kawakami, Koji
- Subjects
STOMACH cancer ,CANCER patients ,POSTOPERATIVE nausea & vomiting ,NAUSEA ,MEDICAL databases ,VOMITING - Abstract
Purpose: In chemotherapy-induced nausea and vomiting (CINV), the superiority of the second-generation 5-hydroxytryptamine-3 receptor antagonist (5-HT
3 RA) over the first-generation 5-HT3 RA is shown in the delayed emesis in cycle 1. We evaluate the antiemetic efficacy in real-world clinical practice that has not been sufficiently investigated in clinical trials. Methods: We included patients who were diagnosed with gastric cancer between April 2012 and June 2017 from the medical claims databases and were treated with cisplatin (≥ 50 mg/m2 ) and standard antiemetic therapy (5-HT3 RA + neurokinin-1 receptor antagonist [NK1RA] + dexamethasone). We compared the second-generation 5-HT3 RA (2nd group) and the first-generation 5-HT3 RA (1st group) groups to evaluate the additional antiemetic drug as the CINV event. Results: In total, 3798 patients were extracted; 1440 and 2358 patients were included in the 1st and 2nd groups, respectively. The clinical and demographic characteristics did not differ between the groups. In the overall (days 1–6) in cycle 1, 51.7% and 44.3% of patients in the 1st and 2nd groups, respectively, had a CINV event. In the acute phase (days 1–2), 38.7% and 30.2% and in the delayed phase (days 3–6), 35.8% and 32.1% of patients in the 1st and 2nd groups, respectively, had a CINV event. Furthermore, the CINV event trend was the same as in cycles 1 to 5. Conclusion: The proportion of CINV events in the 2nd group was smaller than that in the 1st group at any cycle. These findings may suggest consistent antiemetic efficacy of second-generation 5-HT3 RA throughout the cycle. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
3. Responses to depressive symptom items exhibit a common mathematical pattern across the European populations
- Author
-
60796275, Tomitaka, Shinichiro, Kawasaki, Yohei, Ide, Kazuki, Akutagawa, Maiko, Ono, Yutaka, Furukawa, Toshi A., 60796275, Tomitaka, Shinichiro, Kawasaki, Yohei, Ide, Kazuki, Akutagawa, Maiko, Ono, Yutaka, and Furukawa, Toshi A.
- Abstract
The theoretical distribution of responses to depressive symptom items in a general population remains unknown. Recent studies have shown that responses to depressive symptom items follow the same pattern in the US and Japanese populations, but the degree to which these findings can be generalized to other countries is unknown. The purpose of this study was to conduct a pattern analysis on the EU population’s responses to depressive symptom items using data from the Eurobarometer. The Eurobarometer questionnaires include six depressive symptom items from the 12-item General Health Questionnaire. The pattern analysis revealed that, across the entire EU population, the ratios between “score = 2” and “score = 1” and between “score = 3” to “score = 2” were similar among the six items and resulted in a common pattern. This common pattern was characterized by an intersection at a single point between “score = 0” and “score = 1” and a parallel pattern between “score = 1” and “score = 3” on a logarithmic scale. Country-by-country analyses revealed that the item responses followed a common characteristic pattern across all 15 countries. Our results suggest that responses to depressive symptom items in a general population follow the same characteristic pattern regardless of the specific country.
- Published
- 2019
4. Influence of acetaminophen on renal function: a longitudinal descriptive study using a real-world database.
- Author
-
Ide, Kazuki, Fujiwara, Takashi, Shimada, Noriaki, and Tokumasu, Hironobu
- Abstract
Purpose: Long-term acetaminophen (APAP) use has poorly defined effects on renal function. We investigated these effects using a real-world database. Methods: We used a database of health data routinely collected from 185 hospitals serving 20 million patients in Japan. Individuals with chronic pain were selected for the study. The primary outcome was the change in renal function, as measured by 1/serum creatinine (SCr) during the postindex period. Results: After excluding individuals who did not meet the inclusion criteria, 241,167 patients were included in the analysis (median age 79.0, range 65–101 years; 111,252 were men). APAP was prescribed significantly more frequently to patients with a low renal function (P < 0.001). The annual changes in 1/SCr median and interquartile range (IQR) were − 0.038 (− 0.182 to 0.101) in patients receiving APAP, − 0.040 (− 0.187 to 0.082) in patients receiving non-steroidal anti-inflammatory drugs (NSAIDs), and − 0.025 (− 0.142 to 0.079) in nonmedicated control patients (P < 0.001). These changes were not significantly different among patients with a low renal function, with 0.003 (− 0.066 to 0.113) in the APAP group, 0.000 (− 0.089 to 0.090) in the NSAID group, and − 0.009 (− 0.086 to 0.089) in the control group (P = 0.327). Conclusion: Physicians tended to select APAP for individuals with a low renal function. The annual changes in 1/SCr were significantly different based on APAP and NSAID use or no analgesia, but the differences were not significant among patients with a low renal function. Overall, long-term use of APAP does not appear to exacerbate the renal function in a clinical setting. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Landiolol hydrochloride for prevention of atrial fibrillation during esophagectomy: a randomized controlled trial.
- Author
-
Aoki, Yoshitaka, Kawasaki, Yohei, Ide, Kazuki, Shimizu, Yuichiro, Sato, Shinsuke, and Yokoyama, Junichiro
- Subjects
ATRIAL fibrillation ,RANDOMIZED controlled trials ,INTENSIVE care units ,AMBULATORY surgery - Abstract
Introduction: Landiolol hydrochloride reduces the incidence of perioperative atrial fibrillation (AF) in cardiac surgery; however, little evidence is available regarding its effects in other types of surgery, including esophagectomy. We assessed the hypothesis that landiolol reduces perioperative AF and other complications associated with esophagectomy. Methods: This single-center, randomized, double-blind, parallel-group study enrolled patients scheduled for esophagectomy. Patients were divided into those given landiolol at 3 μg/kg/min or placebo for 24 h. The primary outcome was the proportion of patients who developed AF within 96 h starting at 9:00 am on the day of surgery. The secondary outcomes were the proportion of patients whose AF appeared within 24 h, other complications based on the Clavien–Dindo classification, and the intensive care unit and hospital stays. Results: Despite early study termination, 80 patients were screened, and 56 were enrolled (28/group) from September 2016 to June 2018. AF occurred within 96 h of surgery in six (21.4%) patients in the landiolol group and five (17.9%) patients in the placebo group (odds ratio, 1.26; 95% confidence interval, 0.33–4.7) and within 24 h of surgery in three (10.7%) patients in the landiolol group and two (7.1%) patients in the placebo group. There were no significant differences in the incidence of complications or in the number of intensive care unit or hospital stays between the groups. Conclusion: Although our small sample size prevents definitive conclusions, landiolol might not reduce the occurrence of AF or other complications. Trial registration: UMIN, UMIN000024040. Registered 13 September 2016, http://www.umin.ac.jp/ctr/index/htm [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Factors Influencing Placebo Responses in Rheumatoid Arthritis Clinical Trials: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Studies.
- Author
-
Nagai, Kota, Matsubayashi, Keisuke, Ide, Kazuki, Seto, Kahori, Kawasaki, Yohei, and Kawakami, Koji
- Subjects
META-analysis ,CLINICAL trials ,RHEUMATOID arthritis ,UBIQUINONES ,EXPERIMENTAL design ,PLACEBOS ,WESTERN countries - Abstract
Background and Objective: A better understanding of placebo responses and the specific factors influencing these outcomes is important for clinical trial design. We investigated the magnitude of placebo responses at 3 months and the potential factors influencing these outcomes in rheumatoid arthritis (RA) clinical trials. Methods: We conducted a systematic review of randomized placebo-controlled trials of pharmacological agents for RA identified from PubMed, Embase, and Cochrane Central Register of Controlled Trials databases. The primary placebo outcome was American College of Rheumatology 20% response rate (ACR20). Data were pooled with a random-effects model. Factors influencing placebo response were assessed by meta-regression analyses. Subgroup analyses were performed for studies conducted in non-Western countries only versus in Western countries (North America and/or Europe) only or both. Results: The meta-analysis included 88 studies comprising 8406 patients receiving a placebo. The pooled estimate of placebo ACR20 was 29.0% (range 10.0–46.2; 95% confidence interval 27.2–30.9). Placebo ACR20 was negatively associated with trials in non-Western (Asian) countries and patient populations showing an inadequate response to biological disease-modifying antirheumatic drugs (DMARDs) in the multivariable analysis, whereas it was positively associated with the year of publication. No background DMARD treatment was also a negative predictor (albeit statistically non-significant). In subgroup analyses of Western and multiregional studies, study population and publication year were significant factors. Conclusions: Our meta-analysis suggests that study location, patient population, and a background DMARD treatment influence placebo ACR20. These along with placebo response temporal profiles have important implications for designing and interpreting RA clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Laparoscopic versus open repair for inguinal hernia in children: a retrospective cohort study.
- Author
-
Nakashima, Masayuki, Ide, Kazuki, and Kawakami, Koji
- Subjects
- *
INGUINAL hernia , *SURGICAL site infections , *COHORT analysis , *SURGICAL complications , *LAPAROSCOPIC surgery - Abstract
Purpose: We compared the outcomes of laparoscopic surgery (LS) with those of open surgery (OS) for unilateral and bilateral pediatric inguinal hernia. Methods: Using a nationwide claim-based database in Japan, we analyzed data from children younger than 15 years old, who underwent inguinal hernia repair between January 2005 and December 2017. Patient characteristics, incidence of reoperation, postoperative complications, length of hospital stay, and duration of anesthesia were compared between LS and OS for unilateral and bilateral hernia. Results: Among 5554 patients, 2057 underwent LS (unilateral 1095, bilateral 962) and 3497 underwent OS (unilateral 3177, bilateral 320). The incidence of recurrence was not significantly different between OS and LS (unilateral: OS 0.2% vs. LS 0.3%, p = 0.44, bilateral: OS 0.6% vs. LS 0.6%, p = 1.00). The incidence of metachronous hernias was significantly higher in the OS group than in the LS group (4.8% vs. 1.0%, p < 0.001). The surgical site infection rate was significantly lower after OS than after LS for unilateral surgeries (0.9% vs. 2.2%, p = 0.002). There was no difference between OS and LS in the length of hospital stay. Conclusion: Both OS and LS had a low incidence of recurrence in children; however, the incidence of metachronous hernias was lower for LS, which may influence operative technique decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study.
- Author
-
Nakashima, Masayuki, Ide, Kazuki, and Kawakami, Koji
- Abstract
Background: The benefit of regorafenib for colorectal cancer patients was demonstrated in previous randomized studies. However, these studies showed a high rate of treatment-related adverse events, and adverse events were more common in Japanese patients. Some studies showed fewer adverse events and a longer survival time with a reduced initial dose. However, the benefits of a reduced initial dose of regorafenib have only been evaluated in small samples.Objective: Our objective was to analyze the efficacy of initial regorafenib dose reduction compared with a standard dose for colorectal cancer patients.Patients and Methods: We used a hospital-based nationwide claims database. Patients who received regorafenib for metastatic colorectal cancer between June 2013 and July 2017 were included in this study. We divided the patients into a standard initial dose group (standard group) and a reduced initial dose group (reduced group). Overall survival (OS) and adverse events were compared between the two groups. We performed propensity score matching for sensitivity analysis.Results: We included 2376 patients (1208 in the standard group and 1168 in the reduced group). The median OS was 12.3 months (95% confidence interval (CI): 11.0-13.3) in the standard group and 12.6 months (95% CI: 11.7-13.6) in the reduced group. A log-rank test showed no significant difference between the two groups (p = 0.41). Most adverse events occurred less frequently in the reduced group. In the sensitivity analysis, there was no significant difference for OS.Conclusions: No significant difference was observed for OS between the standard group and the reduced group. However, there were fewer adverse events in the reduced group. The optimal initial dose of regorafenib should be identified in further studies. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
9. Preoperative pulmonary function tests before low-risk surgery in Japan: a retrospective cohort study using a claims database.
- Author
-
Yonekura, Hiroshi, Ide, Kazuki, Seto, Kahori, Kawasaki, Yohei, Tanaka, Shiro, Nahara, Isao, Takeda, Chikashi, and Kawakami, Koji
- Subjects
- *
PULMONARY function tests , *PREOPERATIVE period , *OPERATIVE surgery , *PROGNOSTIC tests , *GENERAL anesthesia - Abstract
Purpose: Routine preoperative pulmonary function tests (PFTs) are not recommended prior to low-risk surgery because their prognostic value is limited. However, only a few studies have assessed the utilization of healthcare resources regarding preoperative PFTs in a real-world setting. Here, we aimed to assess the prevalence and determinant factors of preoperative PFTs before low-risk surgery in Japan.Methods: In this retrospective cohort study, we used the nationwide insurance claims databases. Patients who underwent low-risk surgeries under general anesthesia between April 1, 2012, and March 31, 2016, were included. The primary outcome was the receipt of PFTs within 60 days before an index surgery. We performed descriptive analyses to estimate the rates of preoperative PFTs annually starting in 2012, and examined the associations between patient- and institutional-level factors and preoperative PFTs using multilevel logistic regression analyses.Results: The cohort included 9495 procedures (8866 patients) at 1487 institutions. Preoperative PFTs were conducted before 71.8% of the procedures. The temporal trend of preoperative PFTs remained constant from 72.4% in 2012 to 72.2% in 2015. Multilevel regression analysis revealed that preoperative PFTs were associated with older age, number of beds at a medical facility, and inpatient procedures. The median institutional-specific proportion of PFTs was 75.0% (interquartile range, 14.3–100%) with wide inter-institutional variation.Conclusions: Our analysis found that preoperative PFTs were performed before 72% of low-risk surgeries under general anesthesia. Apart from age, preoperative PFTs were determined primarily by non-medical factors. Additionally, we observed substantial institutional variation in the use of preoperative PFTs. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
10. Importance of eliminating potential dental focal infection before the first cycle of chemotherapy in patients with hematologic malignancy.
- Author
-
Shimada, Yasuyuki, Nakagawa, Yumiko, Ide, Kazuki, Sato, Izumi, Hagiwara, Shotaro, Yamada, Hiroshi, Kawasaki, Yohei, and Maruoka, Yutaka
- Subjects
HEMATOLOGIC malignancies ,DENTAL focal infection ,DRUG therapy ,STEM cell transplantation ,PERIOPERATIVE care ,DIAGNOSIS - Abstract
The article reports on the importance of eliminating potential dental focal infection before the first cycle of chemotherapy in patients with hematologic malignancy. Topics discussed include impact of immunosuppressive therapy on the oral cavity infections of the patients; preventing oral health in patients undergoing chemotherapy or pre-hematopoietic stem cell transplantation; and risk of perioperative surgical site infection in eliminate dental focal infection.
- Published
- 2017
- Full Text
- View/download PDF
11. Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis.
- Author
-
Usui, Tomoko, Funagoshi, Masaru, Seto, Kahori, Ide, Kazuki, Tanaka, Shiro, and Kawakami, Koji
- Abstract
Summary: This study investigated the real-world persistence rate and switches of teriparatide-treated patients using a claims database in Japan. The persistence rate of teriparatide at 12 months was 34.9%, and approximately one-third of the patients were not treated with any osteoporosis drugs after teriparatide. Improvement in persistence and switches are desired.Purpose: We aimed to elucidate the persistence rates and switches before and after teriparatide treatment in real-world osteoporosis patients based on data from a medical claims database in Japan.Methods: We reviewed the records of patients with diagnoses of osteoporosis who were prescribed teriparatide at least once from January 2005 to June 2017. Patients with a follow-up ≤ 90 days before the first and ≤ 90 days after the last prescription of teriparatide were excluded. Discontinuation was defined as no treatment for > 90 days. We investigated treatment duration, compared characteristics of patients with persistence ≤ 12 and > 12 months, and osteoporotic medications before and after teriparatide by weekly or daily teriparatide.Results: Among the 553 patients extracted for the study, 81.9% were women, 45.6% were aged ≥ 65 years, and 67.3% had a fracture. The most common fracture site was the spine (39.2%). The overall persistence rate of teriparatide > 12 months was 34.9% (weekly, 23.5%; daily, 43.1%). The subjects with persistence > 12 months comprised a higher proportion of women and they had a higher prevalence of rib and sternum fractures than those with ≤ 12 months. After teriparatide, 38.2% were switched to active vitamin D3, 35.1% to bisphosphonates, and 13.7% to denosumab allowing duplication. However, 34.0% of the patients were not switched to any subsequent medication for osteoporosis.Conclusions: Persistence rate over 12 months of teriparatide treatment was 34.9% in Japan. Approximately one-third of patients had no subsequent treatment immediately after teriparatide. Monitoring persistence and considering subsequent drugs for osteoporosis are necessary for teriparatide treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.